Oxidative Inhibition of the Mitochondrial Aldehyde Dehydrogenase Promotes Nitroglycerin Tolerance in Human Blood Vessels  by Hink, Ulrich et al.
A
w
k
i
t
l
w
i
F
H
a
c
D
G
a
Journal of the American College of Cardiology Vol. 50, No. 23, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
PCardiac Pharmacology
Oxidative Inhibition of the
Mitochondrial Aldehyde Dehydrogenase Promotes
Nitroglycerin Tolerance in Human Blood Vessels
Ulrich Hink, MD,* Andreas Daiber, PHD,* Nalan Kayhan, MD,† Jordis Trischler, MS,*
Catharina Kraatz, MS,* Matthias Oelze, PHD,* Hanke Mollnau, MD,* Philip Wenzel, MD,*
Christian F. Vahl, MD,† Kwok Ki Ho, PHD,‡ Henry Weiner, PHD,‡ Thomas Munzel, MD*
Mainz, Germany; and West Lafayette, Indiana
Objectives We tested the hypothesis of whether an inhibition of the nitroglycerin (GTN) bioactivating enzyme mitochondrial
aldehyde dehydrogenase (ALDH-2) contributes to GTN tolerance in human blood vessels.
Background The hemodynamic effects of GTN are rapidly blunted by the development of tolerance, a phenomenon associ-
ated with increased formation of reactive oxygen species (ROS). Recent studies suggest that ROS-induced inhibi-
tion of ALDH-2 accounts for tolerance in animal models.
Methods Segments of surgically removed arteria mammaria and vena saphena from patients undergoing coronary bypass
surgery were used to examine the vascular responsiveness to GTN and the endothelium-dependent vasodilator
acetylcholine. The ALDH-2 activity and expression in these segments were assessed by the conversion of a benz-
aldehyde or its derivative to the benzoic acid metabolite and by Western blotting technique.
Results In contrast to patients not treated with nitrates (n  36), patients treated with GTN for 48 h (n  14) be-
fore surgery showed tolerance to GTN and endothelial dysfunction in arterial and venous vessels. In vivo
GTN tolerance was mimicked in vitro by incubation of nontolerant vessels with the ALDH-2 inhibitor beno-
myl. In vivo GTN treatment decreased vascular aldehyde dehydrogenase activity compared with nontolerant
vessels and decreased the expression of ALDH-2 in arterial tissue. Incubation of control venous vessels with
GTN caused a significant attenuation of aldehyde dehydrogenase activity that was reversed by presence of
the sulfhydryl group donor dithiothreitol.
Conclusions Long-term GTN treatment induces tolerance and endothelial dysfunction in human vessels, associated with an
inhibition and down-regulation of vascular ALDH-2. Thus, these findings extend results of previous animal studies
to humans. (J Am Coll Cardiol 2007;50:2226–32) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.08.031i
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wlthough nitroglycerin (GTN) has been one of the most
idely used anti-ischemic drugs for more than a century, its
nown drawbacks such as development of tolerance and the
nduction of endothelial dysfunction might limit its use in
he clinical setting (1). Recent studies even indicate that the
ong-term use of mononitrates and dinitrates in patients
ith coronary artery disease after an acute myocardial
nfarction might be even deleterious for patients with
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nd ‡Purdue University, West Lafayette, Indiana. The authors have received
ontinuous funding by the German Research Community (DFG), SFB 553 – C17 to
rs. Daiber and Munzel and MAIFOR grants from the Hospital of the Johannes
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Manuscript received October 13, 2006; revised manuscript received July 10, 2007,
ccepted August 16, 2007.schemic heart disease (2). Although the mechanisms un-
erlying nitrate tolerance are likely multifactorial, recent
tudies indicate that 2 mechanisms such as stimulation of
ascular production of reactive oxygen species (ROS) as well
s an inhibition of the GTN bioactivating mitochondrial
nzyme aldehyde dehydrogenase (ALDH-2) can be consid-
red as primary mechanisms (3,4). This has been demon-
trated not only in animal experiments with specific
LDH-2 knockout (5) and GTN treatment (6) but also in
umans with ALDH-2 Glu504Lys polymorphism (7) as well
s in patients with coronary artery disease undergoing bypass
urgery (8).
More recent in vitro and in vivo data suggest that GTN
reatment increases ROS formation in particular within
itochondria at complex-I of the respiratory chain (9), all of
hich might lead to an inhibition of the activity of the
TN-activating enzyme ALDH-2 (4,10–12).
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December 4, 2007:2226–32 Nitrates, Oxidative Stress, and ALDH-2Some of these involved mechanisms, such as increased
OS production in A. mammaria, endothelial dysfunction,
nd an inhibition of the activity of the cyclic guanosine
onophosphate-dependent kinase I (cGK-I) also have been
emonstrated in patients with coronary artery disease (8). It
emains to be established, however, whether in vivo treat-
ent with GTN leads to an oxidative stress-induced inhibi-
ion of the GTN-metabolizing enzyme ALDH-2 in vascular
issue and whether GTN-induced endothelial dysfunction is
ssociated with a change in the expression of the endothelial
itric oxide synthase gene (eNOS).
ethods
tudy protocol. Patients were retrospectively assigned to a
ontrol group (CTR) without GTN treatment before sur-
ery or to the GTN group being treated with continuous
ntravenous GTN treatment directly before surgery. Pa-
ients on a chronic oral nitrate therapy or intravenous nitrate
herapy for24 h were not included in the study. Exclusion
riteria were concomitant treatment with antioxidants such
s vitamin E and C. This study was approved by the local
thics committee of Mainz, Germany. Informed consent
as given by all patients involved in the study.
The medication and characteristics of all patients partic-
pating in the study are summarized in Table 1. During
urgery, discarded segments of the A. mammaria and V.
aphena were collected. Additionally, in an initial series of
atients (8) segments of A. mammaria, V. saphena, and A.
adialis were collected to be compared in regard to their
ldehyde dehydrogenase (ALDH) activity.
essel preparation and isometric tension studies. To test
or vascular GTN sensitivity and for the determination of
ndothelial function, isolated rings of A. mammaria and V.
aphena vessels were used in organ chamber experiments as
escribed previously (8). Vessels were pre-constricted with
he thromboxane analogue U46619 to achieve 30% to 50%
f maximal (potassium chloride-induced) tone as described
8). For in vitro experiments, vessels from patients without
TN treatment were incubated with the ALDH-2 inhib-
tor benomyl (10 mol/l for 30 min) and tested for GTN
eactivity.
easurement of vascular ALDH activity. For determi-
ation of vascular ALDH activity, vessel rings were incu-
ated with benzaldehyde (400 mol/l) or 2-hydroxy-3-
itrobenzaldehyde (100 mol/l), a more selective ALDH-2
ubstrate, for 30 min at 37°C. The conversion to benzoic
cid or to 2-hydroxy-3-nitrobenzoic acid, respectively, was
easured in the incubation solution as described (10,12).
ne hundred microliters of each sample were subjected to
igh-performance liquid chromatography (HPLC) analysis.
or in vitro incubation experiments, vessel rings were
ncubated with benomyl (100 mol/l for 10 min), GTN
250 mol/l for 60 min or 500 mol/l for 30 min as stated
n the respective figure legends) with or without dithiothre-
tol (DTT) (10 mmol/l for 30 min) at 37°C.
c
estern blot analyses for eNOS
nd ALDH-2 expression.
rozen tissue was homogenized in
iquid nitrogen, subjected to sodium
odecylsulfate-polyacrylamide gel
lectrophoresis (SDS-PAGE) and
ubsequently blotted to nitrocellu-
ose membranes (BioRad, Her-
ules, California). The blots were
eveloped with a mouse monoclo-
al antibody to eNOS (dilution
:1,000; BD Biosciences, San Jose,
alifornia) or a rabbit polyclonal
ntibody to ALDH-2 (dilution
:2,500; kindly provided from
.K. Ho, Purdue University, West Lafayette, Indiana [13]).
oading and transfer were normalized against alpha-actinin for
rterial eNOS and beta-actin for venous eNOS or ALDH-2
antibody dilutions 1:2000; Sigma, St. Louis, Missouri). The
40-kDa eNOS and the 52-kDa ALDH-2 band were quan-
ified by densitometry. The GTN-treated group was compared
ith the mean value in control vessels that was defined as
00%.
tatistical analysis. Results are expressed as mean SEM.
he half-maximal concentration (EC50) value for each
ascular activity experiment was obtained by logit-
ransformation. To compare different vessel types and treat-
ent groups, a 1-way analysis of variance was employed. P
alues  0.05 were considered locally significant with the
atient Characteristics
Table 1 Patient Characteristics
CTR GTN
n 36 14
Age (yrs) 70 1 70 1
GTN treatment period (h) — 47 5
GTN dose (mg/h) — 2.3 0.2
GTN dose (g/kg/min) — 0.5 0.1
Gender, male/female 29/7 12/2
Age 60 yrs (%) 92 100
Hyperlipidemia (%) 64 79
Smoking (%) 31 21
Hypertension (%) 86 93
Family history of CVD (%) 8 0
Diabetes (%) 44 50
Extent of CAD, 1/2/3 VD 1/6/29 0/4/10
Concomitant medication
Beta-blocker (%) 67 93
ACE inhibitor (%) 67 64
AT1-receptor blocker (%) 19 43
Calcium channel blocker (%) 31 14
Statins (%) 72 93
ASS/clopidogrel (%) 64 71
alues indicate the total number of patients/group or mean  SEM.
ACE  angiotensin-converting enzyme; ASS  acetylsalicylic acid; AT1  angiotensin 1; CAD 
oronary artery disease; CTR  control group without in vivo nitroglycerin treatment; CVD 
Abbreviations
and Acronyms
ALDH-2  mitochondrial
aldehyde dehydrogenase
DTT  dithiothreitol
EC50  half-maximal
concentration
eNOS  endothelial nitric
oxide synthase
GTN  glycerol trinitrate,
nitroglycerin
ROS  reactive oxygen
speciesardiovascular disease; GTN  vessels from patients with
vessel disease.intravenous nitroglycerin treatment; VD
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Nitrates, Oxidative Stress, and ALDH-2 December 4, 2007:2226–32atient being the unit of analysis. Owing to very limited and
ariable amounts of waste bypass material, the statistical
nalysis of different treatment groups was performed for
ach individual experimental setting and not in a paired
anner. If more than 1 vessel segment/patient was ana-
yzed, the mean value was used for further statistical
nalysis. The total number of patients and vessel segments
re reported in the figure legends.
esults
tudies of vascular reactivity. Vascular relaxations to
TN and acetylcholine: GTN treatment in vivo caused a
ignificant shift to the right of the GTN dose-response
elationship in A. mammaria and V. saphena, compatible
ith the development of tolerance. Likewise, in vitro
ncubation of these vessels the ALDH-2 inhibitor benomyl
hifted the GTN dose-response curve to a comparable
egree to the right (Fig. 1, Table 2). In both vessel types
tudied, GTN in vivo caused a significant degree of endo-
helial dysfunction in A. mammaria and V. saphena seg-
ents (Table 2).
ascular ALDH activity. Intravenous GTN treatment
nhibited the ALDH activity. In vitro incubation with the
LDH-2 inhibitor benomyl suppressed ALDH activity in
essels of patients without GTN pretreatment by approxi-
ately 75% (Fig. 2). Likewise, in vitro incubation of vessels
f patients without GTN pretreatment with GTN attenu-
ted ALDH activity markedly (Fig. 2). The use of the
lternative substrate, benzaldehyde, to test for dehydroge-
ase activity of ALDH revealed that GTN strongly inhib-
ted ALDH activity that could be prevented by co-
ncubation with the dithiol compound dithiothreitol
Fig. 3), pointing to a redox-sensitive regulation of the
uman ALDH enzyme system. Further analysis of ALDH
ctivity from A. mammaria, A. radialis, and V. saphena
Figure 1 Effects of In Vivo Nitroglycerin Treatment and In Vitro
Effects of in vivo nitroglycerin (GTN) treatment and of in vitro inhibition of the vasc
of A. mammaria (left panel) and V. saphena (right panel). In vivo GTN treatment c
with tolerance. The shift was almost identical as compared with that obtained with
to chronic GTN treatment. Data are mean  SEM from 5 to 9 patients representin
ment versus without pretreatment. CTR  control group.ypass graft material revealed that the weight-normalized
ctivity was highest in A. mammaria, followed by V.
aphena and radial arteries (Table 3).
ffects of GTN treatment on eNOS and ALDH-2
rotein expression. The GTN treatment led to a signifi-
ant decrease in protein expression of the eNOS and
LDH-2 by about 40% in A. mammaria (Figs. 4 and 5).
o change in eNOS expression was detected in V. saphena
egments in response to GTN in vivo treatment.
iscussion
ith the present study we show that in vivo GTN treatment
or approximately 48 h causes tolerance in venous and arterial
ypass vessels that is associated with an inhibition of vascular
itochondrial ALDH activity, the GTN bioactivating en-
yme. Tolerance in A. mammaria was associated with a
ignificant decrease in ALDH-2 expression. In control vessels,
he inhibition of ALDH-2 activity could be mimicked in vitro
y incubation with GTN or the ALDH-2 inhibitor benomyl.
he antioxidant DTT restored ALDH-2 activity, suggesting
hat ROS are likely causally involved in the inhibition of the
nzyme in response to GTN therapy.
Nitrates are still widely used for the treatment of acute
oronary syndrome and acute and chronic congestive heart
ailure. The anti-ischemic and vasodilator properties of
TN, however, are rapidly blunted, owing to the develop-
ent of nitrate tolerance that occurs within 1 to 3 days of
ontinuous treatment. The 2 mechanisms accounting for
his involve mainly an increase in oxidative stress (3,14) and
n impairment of the ALDH-2 mediated GTN biotrans-
ormation process within the vascular tissue itself (4). Re-
ently, we were able to demonstrate that, similar to results
btained in experimental animals (3,14,15), in vivo GTN
reatment averaging 0.5 g/kg/min for 48 h causes a marked
H Inhibition on Nitroglycerin Reactivity in Human Bypass Vessels
dehyde dehydrogenase (ALDH) with benomyl on GTN dose–response relationship
a marked shift of the GTN dose–response relationship to the right compatible
LDH inhibitor benomyl, compatible with an inhibition of the enzyme in response
13 vessel segments/group (see Table 2). p  0.05 of GTN or benomyl treat-ALD
ular al
auses
the A
g 9 to
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nase.
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December 4, 2007:2226–32 Nitrates, Oxidative Stress, and ALDH-2egree of tolerance in humans (8). This was associated with
ndothelial dysfunction and an inhibition of the activity of the
GK-I, the enzyme being of utmost importance for GTN-
nduced vasorelaxation (8).
We proposed, as a predominant mechanism for tolerance
nd endothelial dysfunction, that GTN-induced increases
n the formation of ROS account for both phenomena. The
Figure 2 Effects of In Vivo and In Vitro Nitroglycerin Treatment
In vivo nitroglycerin (GTN) treatment, in vitro GTN, as well as the use of benomyl m
panel) and V. saphena (right panel). n  number of patients/vessel segments/gr
vessel types.
Effects of In Vivo GTN Treatment or In Vitro ALD
Table 2 Effects of In Vivo GTN Treatment or
Vessel Group
Potency (log
GTN
A. mammaria
CTR 7.83 0.15
n 9/17
GTN 7.29 0.08*†
n 8/9
BENO 7.07 0.08†
n 5/10
V. saphena
CTR 7.70 0.11
n 6/10
GTN 6.89 0.12†
n 7/13
BENO 6.97 0.11†
n 7/11
Each value is the mean  SEM of the indicated number of experim
concentrations (EC50) are concentrations that produced 50% of maxim
treatment; GTN  rings from patients with IV GTN treatment before su
at 37°C in vitro. *p  0.05 versus V. saphena; †p  0.05 versus CTR
ACh  acetylcholine; ALDH-2  mitochondrial aldehyde dehydrogeesults of the present studies go along with this concept,
ecause we found that GTN treatment for 48 h in a
oncentration averaging 0.5 g/kg/min caused a compara-
le degree of tolerance and endothelial dysfunction in
atients undergoing bypass surgery.
mpaired biotransformation as well as oxidative stress
ontribute to tolerance. Recently, the group of Stamler
ascular ALDH Activity in Human Bypass Vessels
ly inhibited aldehyde dehydrogenase (ALDH) activity in both A. mammaria (left
shown. p  0.05 versus without GTN pretreatment (CTR); §p  0.05 between
nhibition on Vascular Reactivity
itro ALDH-2 Inhibition on Vascular Reactivity
[mol/l]) Efficacy (maximal relaxation %)
ACh GTN ACh
.50 0.08 94.5 3.6 89.4 2.9*
13/23 9/17 13/23
.94 0.11† 91.6 5.5 82.1 5.7*
5/10 8/9 5/10
98.9 0.9
5/10
.31 0.13 100.0 0.03 74.7 3.6
5/9 6/10 5/9
.92 0.29 88.4 3.9† 39.9 6.2†
4/6 7/13 4/6
96.7 1.4†
7/11
 number of patients/number of vessel rings). The half-maximal
ation to each drug. Groups: CTR rings from patients without nitrate
ENO  CTR-rings after 30 min of incubation with 10 mol/l benomylon V
arked
oup asH-2 I
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Nitrates, Oxidative Stress, and ALDH-2 December 4, 2007:2226–32t al. (4) proposed that the enzyme ALDH-2, located in
itochondria, represents the nitrate reductase responsible
or bioactivation of GTN. This assumption was based on
n vitro and in vivo experiments showing that more or less
pecific inhibitors of the enzyme (4,16), such as cyanamide,
hloral hydrate, as well as acetaldehyde, shifted the GTN
ut not the sodium nitroprusside dose response curve to the
ight, as in vitro incubations of vascular tissue with high-
ose GTN (in vitro tolerance). Inhibitors blocked the
TN-induced increases in cGMP in isolated aortic rings.
ecently, these studies were extended to studies in ALDH-
/ mice supporting the initial findings (5). Importantly,
TN bioactivation by ALDH-2 and subsequent tolerance
henomena might be limited to lower, therapeutically
elevant GTN concentrations (5), and the ALDH-2 does
ot seem to be involved in the biotransformation process of
ono- and dinitrates (1).
In a recent study, we were able to demonstrate that the
mpaired GTN biotransformation concept as well as the
xidative stress concept are closely related to each other
10). With these studies we found that acute incubation of
itochondria in vitro with GTN leads to an increase in
OS production associated with an inhibition of the mito-
hondrial ALDH-2 (10). These findings were extended by
ur in vivo observations demonstrating that GTN treatment
f Wistar rats for a 3-day period increased mitochondrial
OS production and inhibited simultaneously the activity
f the enzyme (12). In addition, endothelial cells without
itochondria showed no increase in cGMP levels in re-
ponse to GTN as compared with endothelial cells with
itochondria (10). Thus, the current unifying concept of
olerance proposes that in vivo treatment with GTN in-
reases oxidative stress within mitochondria at complex-I of
Figure 3 Effects of the Antioxidant
Dithiothreitol on ALDH Activity in V. Saphena
Incubation of V. saphena with nitroglycerin (GTN) markedly inhibited aldehyde
dehydrogenase (ALDH) activity, all of which was prevented by co-incubation with
dithiothreitol (DTT); data are mean  SEM from 6 to 7 experiments. p  0.05
versus without treatment (CTR).he respiratory chain (9), all of which might cause oxidation
mf critical sulfhydryl (SH)-groups near the active center of
he ALDH, thereby leading to an inhibition of the enzyme
6). This hypothesis was further strengthened by recent
tudies in mice with heterozygous manganese superoxide
ismutase knockout, which have (owing to partial deficiency
n this antioxidative protein) increased mitochondrial oxi-
ative stress and simultaneously showed increased suscepti-
ility for the development of nitrate tolerance (12).
To test whether this concept might also apply to human
essels, tissue from the A. mammaria and V. saphena of
atients undergoing bypass surgery were incubated with the
ensitive and specific inhibitor of the ALDH-2 benomyl.
nterestingly, the rightward shift in the GTN dose-response
elationship in vascular tissue from patients without GTN
retreatment was almost identical as compared with the one
bserved in vessels from intravenously GTN-treated pa-
ients. In parallel, we found a significant inhibition of the
ctivity of the ALDH-2. Likewise, incubation of both
rteries and veins from control group patients with GTN (in
itro tolerance) resulted in a significant inhibition of the
ctivity of the enzyme. Thus, it is conceivable to conclude
hat in vivo tolerance induced with clinically relevant con-
entrations of GTN is at least in part secondary to an
nhibition of the ALDH-2. This concept is further supported
y recent clinical trials indicating that a point mutation in
LDH-2 (leading to an inactive enzyme), which appears in
igh prevalence in Asian people, decreases GTN vasodilator
otency (7).
With the present study we found no difference in GTN
otency between human V. saphena and A. mammaria in
ontolerant tissue (Table 2). The 3 vessel types studied
iffered with respect to their ALDH activity being the
ighest in A. mammaria and the lowest in the radial artery
Table 3). These findings suggest that GTN bioactivation
ight differ throughout the body without a general prefer-
nce for either arteries or veins. Nevertheless, we cannot
xclude that, for example, the more traumatic preparation of
he vein and the radial artery might have decreased to some
xtent their ALDH-activity. In addition, we do not know
hether veins in situ react more sensitively to GTN
ompared with excised veins.
To test for redox sensitivity of ALDH-2 activity as a
ossible mechanism for its GTN-induced inhibition, hu-
an V. saphena was incubated with GTN in presence or
bsence of the sulfhydryl-group donor DTT. The finding
LDH Activity in Human Bypassraft Vessels Without Prior GTN Treatment
Table 3 ALDH Activity in Human BypassGraft Vessels Without Prior GTN Treatment
Benzoic Acid
[mol/l/mg] SEM n
A. mammaria 9.8 0.8 15
A. radialis 3.6 0.3 10
V. saphena 4.3 0.3 8
onversion of benzaldehyde (400 mol/l) to benzoic acid was measured by high-performance
iquid chromatography. Mean data  SEM; n indicates number of patients/group from 27 to 41
easurements/group.
ALDH  mitochondrial aldehyde dehydrogenase; GTN  nitroglycerin.
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December 4, 2007:2226–32 Nitrates, Oxidative Stress, and ALDH-2hat DTT completely restored ALDH-2 activity further
ubstantiates the concept of an oxidative stress-induced
nhibition of the enzyme. Likewise, Sage et al. (17) dem-
nstrated impaired GTN biotransformation in vessels from
atients undergoing bypass surgery, who were treated with
TN (0.15 g/kg/min) for 24 h and simultaneously in-
reased oxidative stress as assessed by lucigenin-enhanced
hemiluminescence.
Figure 4 Effects of Nitroglycerin Treatment on eNOS Expressio
Nitroglycerin (GTN) treatment led to a significant decrease in endothelial nitric oxid
expression in V. saphena was not affected. Data are mean  SEM from n  9 to
Figure 5 Effects of Nitroglycerin
Treatment on ALDH-2 Expression
Nitroglycerin (GTN) treatment led to a significant decrease in mitochondrial
aldehyde dehydrogenase (ALDH-2) expression in A. mammaria compared with
control subjects. Data are mean  SEM from n  10 to 12 experiments/group.
p  0.05 versus without GTN treatment (CTR).tIn the present study, in vivo GTN treatment not only
nhibited ALDH-2 activity but also decreased its expression
n the A. mammaria substantially by approximately 40%.
his finding goes along with a more recent publication
here we could establish in an animal model of nitrate
olerance that GTN therapy markedly down-regulates
LDH-2 expression in rat aorta (6).
echanisms underlying GTN-induced endothelial dys-
unction. As shown repeatedly, tolerance is associated with
marked degree of cross tolerance to the endothelium-
ependent vasodilator acetylcholine. Previously, we and
thers have proposed that this phenomenon is rather sec-
ndary to a GTN-induced increase in ROS production
hroughout the vessel wall, leading to enhanced NO break-
own and subsequently to an increase in endothelial per-
xynitrite production (18). Peroxynitrite per se is a strong
timulus for the oxidation of the eNOS cofactor BH4 to the
H3
● radical or BH2 (19), all of which might lead to an
ncoupling of the enzyme, meaning that the enzyme pro-
uces superoxide instead of NO. Indeed, this uncoupling
eaction has been confirmed previously in an animal model
f nitrate tolerance (14).
The results of animal studies also indicated that endo-
helial dysfunction was associated with an up-regulation
ather than a down-regulation of eNOS (6). The results of
he present study show that GTN treatment decreases the
xpression of the enzyme in human A. mammaria but did
ot significantly change the expression in veins. Thus, on
uman Bypass Vessels
hase (eNOS) expression in A. mammaria, whereas eNOS
periments/group. p  0.05 versus without GTN treatment (CTR).n in H
e synt
11 exhe basis of these heterogenous results it remains to be
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Nitrates, Oxidative Stress, and ALDH-2 December 4, 2007:2226–32etermined whether changes in eNOS expression do con-
ribute to endothelial dysfunction at all.
ummary and clinical implications. The results of the
resent studies clearly show for the first time that in vivo
reatment of patients with established coronary artery dis-
ase with GTN for more than 24 h causes tolerance that was
ssociated with a marked inhibition of the ALDH-2 and a
ignificant decrease in the expression of the enzyme. The
ctivity of the enzyme could be restored by the dithiol
ompound DTT. Thus, the experimental concept that
TN induces oxidative stress and leads to an inhibition of
he GTN metabolizing enzyme (10) also seems to hold true
n the clinical setting. Future studies have to demonstrate
hether the use of, for example, mitochondria-specific
ntioxidants might help to prevent the development of
ndothelial dysfunction and tolerance in response to GTN
n patients or whether organic nitrates, being able to
timulate antioxidant pathways such as heme oxygenase (6),
ight be the preferable nitrate in the future treatment of
atients with stable/unstable coronary artery disease or
hronic congestive heart failure.
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